U.S. Modelna Corona Vaccine “94.5% Effectiveness” Provisional Results Announced November 16 at 11:37 PM
Modela, an American pharmaceutical company, has announced tentative results for a new coronavirus vaccine under development that is “94.5% effective.” Modelna said the percentage of effects may change as clinical trials progress in the future.
Modela, an American pharmaceutical company that develops vaccines for the new coronavirus, is conducting a third-stage clinical trial in the United States in cooperation with the National Institutes of Health and other organizations in the United States.
Modela today released preliminary results that analyzed previous data from clinical trials.
As a result, out of more than 30,000 clinical trial subjects, 95 were infected with the new coronavirus.
Of these, five were vaccinated, whereas 90 were vaccinated against a placebo called a placebo, and Modela said the effectiveness of the vaccine was 94.5%.
In addition, there were 11 cases of severe disease, but none of them were in the group that was vaccinated in the group that received the placebo.
Modelna states that no serious safety concerns have been reported to vaccinated people, but 9.7% of people felt lazy after the second vaccination, 8.9% had muscle pain, 5.2% had joint pain, and 4.5% had headaches in 4.5%.
Modelna said that the assessment of the effects may change as the trial progresses, and that the results of clinical trials will be submitted to scientific journals that need to be reviewed in the future.
Modela is also applying to the FDA’s U.S. Food and Drug Administration for emergency use in the near future, and the company said it will be able to ship approximately 20 million shipments to the U.S. by the end of this year, and will be able to produce 500 to 1 billion times worldwide next year.
The Japanese government is also contracted to receive 25 million vaccines from Modela, of which 20 million will be supplied between January and June next year.